Prostate Cancer Imaging: Which Test When

Quick Answer

Prostate cancer imaging selection has been reshaped by PSMA PET/CT, which now outperforms older PET tracers and conventional imaging (CT, bone scan) for initial staging of high-risk disease and for biochemical recurrence, and simultaneously serves as the companion diagnostic for PSMA radioligand therapy. Fluciclovine (¹⁸F) and choline were the prior standards for recurrence and retain a role where PSMA agents are unavailable, but their sensitivity at low PSA is lower. FDG is not a primary prostate tracer but matters late, to identify dedifferentiated, PSMA-negative disease. The choice depends on disease phase (staging vs recurrence), PSA level, and whether PSMA-directed therapy is being considered.

The decision in one place

For high-risk initial staging and for biochemical recurrence, PSMA PET/CT is the preferred test — highest detection, especially at low PSA, and it defines PSMA-therapy eligibility. Use fluciclovine or choline when PSMA is unavailable. Bring in FDG in advanced castration-resistant disease to expose PSMA-negative, aggressive lesions (the discordance that governs radioligand-therapy selection).

Head-to-head

How to sequence

By disease phase:

• Initial staging, high-risk disease: PSMA PET/CT for nodal and distant disease — more accurate than CT + bone scan, and it changes management in a meaningful fraction of patients.
• Biochemical recurrence after definitive therapy: PSMA PET/CT first; its detection advantage is greatest at low PSA, where localizing disease guides salvage therapy. Use fluciclovine/choline if PSMA is unavailable.
• Considering PSMA radioligand therapy (mCRPC): PSMA PET confirms target expression; add FDG to detect PSMA-negative/FDG-positive disease that would be undertreated (the discordance concept).
• Osteoblastic bone-burden questions / Ra-223 candidacy: conventional bone scintigraphy still informs the extent of symptomatic osteoblastic metastases.

Selection concepts

Two ideas drive the choice. First, PSMA PET's sensitivity advantage is largest at low PSA, which is exactly where early recurrence must be localized to enable curative-intent salvage — this is why it displaced choline/fluciclovine. Second, PSMA imaging and PSMA therapy are a matched pair: the same target that lights up the scan is the therapeutic target, so PSMA PET both stages disease and screens for radioligand-therapy eligibility — with FDG added to catch the target-negative, aggressive disease the therapy cannot treat.

Pitfalls in selection

• Benign PSMA uptake (celiac and other ganglia, healing ribs/fractures, Paget, some other tumors) must not be over-called as metastasis, especially when judging therapy eligibility.
• Very low PSA still limits any tracer; detection rises with PSA and PSA kinetics.
• PSMA-negative disease exists — a "clean" PSMA scan does not exclude aggressive FDG-avid disease in advanced cases.

Bottom line

PSMA PET/CT is the preferred test for high-risk staging, biochemical recurrence, and PSMA-therapy selection; fluciclovine/choline substitute when PSMA is unavailable; FDG exposes PSMA-negative advanced disease; and conventional bone scan still informs osteoblastic burden.

Self-Check

Key References

• SNMMI/EANM PSMA PET procedure standards and appropriate-use guidance; prospective staging and recurrence trials (e.g. proPSMA, PSMA PET recurrence cohorts).
• Comparative data on PSMA vs fluciclovine/choline detection by PSA, and dual PSMA/FDG imaging for therapy selection.